ライフサイエンスコーパス: option

1 vaginal moisturizers may be tried as a first option.

2 adiotherapy has emerged as a valid treatment option.

3 reefs to past configurations is no longer an option.

4 ile ignoring their alternative cocaine alone option.

5 risks, probable benefits, and costs of each option.

6 with the drug when considering the treatment option.

7 process and identifying the best therapeutic option.

8 dexamethasone seems to be the best treatment option.

9 penicillin an increasingly viable treatment option.

10 ome pregnant, avoiding alcohol is the safest option.

11 tion of PDT as a first-line cancer treatment option.

12 ive inhibitors as an alternative therapeutic option.

13 s with recombinant human IL-7 as a treatment option.

14 ering of plants offers an alternative supply option.

15 d between exploring and exploiting rewarding options.

16 and discuss with patients smoking cessation options.

17 on, patient pathology, and patient treatment options.

18 in constraining the decision to the relevant options.

19 bout the cancer, and may suggest therapeutic options.

20 Radium-223 and sipuleucel-T also are options.

21 en and deep brain stimulation, are promising options.

22 of chemotherapy and had no further curative options.

23 are emerging worldwide, limiting therapeutic options.

24 otential patient complications and treatment options.

25 veness ratio (ICER) between test and no-test options.

26 erogeneous phenotype and limited therapeutic options.

27 ing victims disfigured and without treatment options.

28 sive loss of vision, and limited therapeutic options.

29 exploration of potential targeted treatment options.

30 sight into the differences between treatment options.

31 imab in combination are documented treatment options.

32 ric cancer and lack of reliable surveillance options.

33 se existing compounds and expedite treatment options.

34 can influence choices among other (relevant) options.

35 have a poor prognosis and limited treatment options.

36 to subsequently discriminate between reward options.

37 and cost-effectiveness of alternative policy options.

38 ets for the development of novel therapeutic options.

39 ntext of DCM, a disease with few therapeutic options.

40 ages compared to traditional electrification options.

41 be considered when designing new therapeutic options.

42 tional enrichments, and streamlined download options.

43 and enable a range of heterogeneous analysis options.

44 ighlighting the need for effective treatment options.

45 are used to update expected values of choice options.

46 in analogue therapy have limited therapeutic options.

47 ss legs syndrome could lead to new treatment options.

48 y the postdecisional devaluation of unchosen options.

49 with effective but rarely curative treatment options.

50 devastating malignancy with few therapeutic options.

51 t can enhance or replace current therapeutic options.

52 mechanisms independent of current treatment options.

53 n, life-threatening, and without therapeutic options.

54 ials were identified, including 18 treatment options.

55 isease with few, if any, effective treatment options.

56 gaps and inadequacies of current therapeutic options.

57 tatic cascade and the paucity of therapeutic options.

58 essors with drug targets informs therapeutic options.

59 viral agents (DAAs) have limited retreatment options.

60 neous malady with limited standard treatment options.

61 in metastases (BrM) have limited therapeutic options.

62 aggressive disease with limited therapeutic options.

63 istance, necessitating alternative treatment options.

64 e EF-G by providing alternative base-pairing options.

65 ortality, uncertain cause, and few treatment options.

66 ission were generally ranked as the two best options.

67 as "decoy effect": introducing an irrelevant option (a decoy) can influence choices among other (rele

68 nostic impact, and the way current treatment options affect the dynamic lesion and exercise hemodynam

69 ibitors (bPIs) represents the only available option after first-line failure for the majority of indi

70 duce a cost-effective and efficient ointment option after undertaking further work to look at its use

71 There are no treatment options against MERS-CoV for humans or animals, and ther

72 nstrate that pattern recognition is a viable option and has functional advantages over direct control

73 small research groups to a scalable storage option and simple data integration, including database a

74 s as VCF, but with multiple high compression options and data access using high-performance parallel

75 quadruple therapies as first-line treatment options and determine factors associated with treatment

76 We explore current antifungal treatment options and discuss promising strategies to impede the e

77 Design of antiviral treatment options and elucidation of the mechanistic basis of dise

78 e new user interface supports diverse search options and graphic representation of fusion gene struct

79 strategy at any time, eliminating all other options and opportunities to learn.

80 Otherwise, the technical options and policy and enabling environment that are nee

81 Improved therapeutic options and prolonged survival have further increased th

82 afe and effective approach expands treatment options and should be considered as a non-pharmacologica

83 ween the expected values of current response options and the actual received rewards and punishments.

84 chiatry, comparative analyses of therapeutic options and the aggregation of data from clinical trials

85 n to aluminium hydroxide (Al) is a promising option, and establishing its effectiveness in the target

86 Several pharmacological treatment options are available for type 2 diabetes; however, many

87 No therapeutic options are available to pregnant women with ZIKV infect

88 or patients with HAE-FXII, various treatment options are available which completely or at least parti

89 Multiple treatment options are available, but existing guidelines provide i

90 Therapeutic options are limited and novel treatments are urgently re

91 Treatment options are limited, due to antifungal resistance.

92 ression of SS18-SSX fusions, where treatment options are limited.

93 r treatment of these patients, and treatment options are limited.

94 However, current options are obtrusive, difficult to implement, and limit

95 ng in which choices of high-cost/high-reward options are sharply increased.

96 nly antibodies (VHHs) are becoming a salient option as immunoassay reagents.

97 n by choosing whether to present that target option as the default.

98 oxifen followed by exemestane are reasonable options as adjuvant endocrine therapy in postmenopausal

99 physician-assisted suicide should be a legal option at the end of life.

100 Currently the only viable option available for comprehensive brain methylome studi

101 cleral contact lenses are some of the latest options available for treating DED.

102 owledge gaps, and present an overview of the options available to coastal resource managers during a

103 understands the severity of the illness and options available to the patient (as determined and docu

104 ant A. fumigatus and address the therapeutic options available.

105 denoma can be offered average-risk screening options beginning at age 40 years.

106 ychiatric condition with limited therapeutic options beyond monoaminergic therapies.

107 ive immobilization to Cr(III) is a treatment option, but its success depends on the long-term potenti

108 dditional corticosteroid therapy, are common options, but optimal management has not been determined.

109 s) to nudge others toward selecting a target option by choosing whether to present that target option

110 and nutrient transport display convergent co-option by placental and mammary gland cell types to opti

111 As treatment options coalesce around a smaller number of antiretrovir

112 sh ceritinib as a more efficacious treatment option compared with chemotherapy in this patient popula

113 ngue diagnosis and the laboratory diagnostic options currently available.

114 Limited options decreased slightly until 2007 (35-33%) and then

115 rs, hypomethylating agents are the preferred option, even though their impact on leukemic transformat

116 cancer with poor prognosis and few treatment options following progression on platinum-containing che

117 CT-P10 might represent a new therapeutic option for advanced-stage follicular lymphoma.

118 iplatelet therapy is the preferred treatment option for carotid dissections.

119 The only curative option for CMML remains allogeneic stem cell transplanta

120 The results support the option for dose-dense PTX chemotherapy with active singl

121 BOc graft combination seems to be a feasible option for expanding the donor pool without additional d

122 Levofloxacin-containing regimens could be an option for first-line treatment, but its efficacy should

123 aminoacids, as surfactants, are an excellent option for food industry due to the currently trends in

124 , providing evidence that LDR is a promising option for future treatment strategies to prevent cancer

125 e-based superconductors, may provide another option for high-field-magnet wires.

126 eous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previous

127 d thalamic DBS might be a safe and effective option for improving severe, refractory multiple scleros

128 results demonstrate that the most effective option for individuals to decrease revenue variability i

129 MIPs are a promising option for industrial packed and fluidized bed CO2 captu

130 NAVETTA is a novel option for mimicking human lung cell exposure to NPs, co

131 processes and therefore could be a treatment option for MS, because it combines features of immunomod

132 hat gene therapy may represent a therapeutic option for NPC1 patients and suggest that extraneuronal

133 nces and should be considered as a treatment option for opioid-dependent individuals.

134 ic approach can be considered as a treatment option for OSA and other motorneuron disorders.

135 lt, pembrolizumab has become a new treatment option for patients who are cisplatin-ineligible or not

136 surveillance should be an initial management option for patients who have significant comorbidities a

137 efficacy of atraumatic needles as a superior option for patients who require lumbar puncture.

138 might be a tolerable, efficacious treatment option for patients with advanced melanoma.

139 eresis and intravenous immunoglobulins is an option for patients with AMR.

140 BF2/OIT may provide an additional OIT option for patients with concurrent PN/TN and other food

141 se, targeting C5aR1 may serve as a treatment option for patients with Gaucher disease and, possibly,

142 thout RBV is an effective and safe treatment option for patients with HCV genotype 4 infection in pre

143 ruption in rods may be a promising treatment option for patients with retinitis pigmentosa.

144 was recently introduced as a novel treatment option for pulmonary hypertension.

145 We suggest rituximab as a viable treatment option for recalcitrant DH.

146 eptor activation might provide a therapeutic option for renoprotective therapy.

147 17beta-estradiol levels as a novel treatment option for SERT deficiency associated obesity and metabo

148 plantation (HSCT) remains the only treatment option for several severe hematological malignancies.

149 n pharmacological hypothermia as a treatment option for stroke.

150 agonists, representing a potential treatment option for such patients.

151 l covariates evaluated by using the stepwise option for the selection.

152 r vesicles could display a novel therapeutic option for the treatment of cardiovascular diseases.

153 LOXL2 catalytic activity represent a useful option for the treatment of fibrosis.

154 ry BCAAs may represent a highly translatable option for the treatment of obesity and insulin resistan

155 TMVR) has emerged as a potential therapeutic option for the treatment of severe MR.

156 omega-TAms have emerged as an exciting option for their synthesis, offering a potential "green

157 orectal cancer, and could be a new treatment option for these patients.

158 ab may be further evaluated as a therapeutic option for this rare disease.

159 rs may be beneficial, and surgery remains an option for those with symptoms or treatment complication

160 for using s.c. islet delivery as a treatment option for type I diabetes, the more immediate benefit m

161 Conclusion ROCA-based screening is an option for women at high risk of OC/FTC who defer or dec

162 vide a scientific rationale and three policy options for all levels of government to meaningfully enh

163 espite this effort, however, pharmacological options for ARDS remain scarce.

164 However, options for assessing electrophysiological activity in t

165 osine kinase inhibitors (TKIs) are treatment options for brain metastases in patients with EGFR-mutan

166 for prognostic, diagnostic, and therapeutic options for cardiovascular disease prevention.

167 Antiviral treatment options for chronic Hepatitis E Virus (HEV) infections a

168 Intraarterial therapy options for colorectal liver metastases include chemoinf

169 s/progenitor cells may provide new treatment options for combating nasal polyposis.

170 There are currently no options for curing this infection.

171 ancer and may provide specific and selective options for diagnosis as well as for therapeutic interve

172 variate random forests that includes various options for error estimation techniques.

173 simulators, FastSimBac provides more general options for evolutionary scenarios, allowing population

174 Options for facilitating the shift from volume to value

175 We discuss options for gene delivery experiments to test circuit an

176 ost half of all cases of deafness, treatment options for genetic deafness are limited.

177 ime we must choose between exploring unknown options for information and exploiting known resources f

178 Current therapeutic options for initial surgery and chronic heart failure th

179 ce and suggests new biomarkers and treatment options for lapatinib-resistant cancers.

180 eater overexploitation or staying at current options for longer than is optimal.

181 Physicians guideline addressed pharmacologic options for low back pain.

182 Options for managing splenic injuries have evolved with

183 in situ/operando approaches demonstrates new options for monitoring WOC transformations.

184 Although medical treatment options for NEC are largely unchanged, understanding of

185 eeking diagnostic evaluation and therapeutic options for nonhealing facial erosions occurring after a

186 Beyond optical techniques, however, options for noninvasive imaging of nanodiamonds in vivo

187 n be used to help identify potential therapy options for patients harboring oncogenic genomic alterat

188 Treatment options for patients who failed previous DAA-containing

189 changed the landscape of available treatment options for patients with advanced cancer.

190 therapy is providing exciting new treatment options for patients with PIDs, and advances are sure to

191 genic etiologies, and the rational treatment options for people with these neoplasms.

192 between system-wide and superemitter policy options for reducing methane emissions from compressor s

193 known risk factors, symptoms, and suggested options for screening and treatment are given.

194 ndard of care, I discuss currently available options for standard therapy and existing clinical data.

195 -driven Friedel-Crafts acylation offers more options for tailoring the properties and processing of c

196 sis of this disease has identified potential options for targeted therapeutic intervention.

197 oorly understood, hence representing limited options for targeted therapies.

198 appear promising and may be more convenient options for the imaging and assessment after treatment.

199 openia in patients with NASH and therapeutic options for the management of sarcopenia.

200 y, after presenting assessment and treatment options for the practicing hematologist, we propose elem

201 ts is warranted, because they may define new options for the treatment of solid cancers.

202 Moreover, novel medical options for the treatment of stroke patients are also un

203 Treatment options for these mood disorders are currently suboptima

204 Compared with standard options for this indication, our results show that nivol

205 ed during past 27 years, the authors discuss options for transitioning GPLN assets to support control

206 viour interfering strategies, increasing the options for translational research in the vector control

207 eptance of anti-obesity drugs as appropriate options for treatment.

208 We have recently discussed options for using assisted evolution (i.e., selective br

209 very and new classifications and therapeutic options for various forms of hydrocephalus and idiopathi

210 The management options for VMT include pars plana vitrectomy, pneumatic

211 Finally, treatment options for VWD are reviewed, including the use of recom

212 The transducing options function together with suitable nanoparticles: m

213 The exhaustive Kmer-SSR option has 100% precision and 100% recall and accurately

214 Thus, enthusiasm for LAAC as a treatment option has been appropriately tempered, particularly as

215 Purpose Since 2000, many new treatment options have become available for relapsed and/or refrac

216 ous thermal ablation should be considered an option if complete ablation can reliably be achieved.

217 agnostic procedure and are used as the first option in almost two-third of all types of allergic dise

218 bitors (RTIs) were proposed as a therapeutic option in autoimmunity ensuing from defects of TREX1.

219 tion was the least effective and most costly option in both risk groups.

220 2 S albumins has shown to be a valuable new option in diagnostic procedure.

221 LRP3 inflammasome activation may offer a new option in the treatment of inflammatory bowel disease.

222 support nivolumab as a new standard-of-care option in this setting.

223 prognostication, and emerging new treatment options in advanced systemic mastocytosis.

224 ; assess and implement established treatment options in patients with CKD; improve management of symp

225 Further evaluation of these new therapeutic options in well-designed prospective multicenter trials

226 the opportunity to discuss various treatment options, including organ-sparing TMT.

227 ople first assess the attractiveness of each option independently of each other and then pick the opt

228 highlight the chemically different reaction options influenced by the distal histidine ligand.

229 the hypothesis that the presence of a decoy option influences the valuation of other options, making

230 came to pursue their CeA ChR2-paired cocaine option intensely and exclusively, elevating cocaine inta

231 ted protease inhibitor regimens, this policy option is also predicted to lead to a reduction of overa

232 However, such an option is only feasible for patients who require a moder

233 of neuropathy, a bortezomib-rituximab-based option is reasonable for relapsed or refractory disease.

234 t, which is the tendency to choose whichever option is the status quo.

235 ow to optimally counsel women about surgical options is warranted.

236 till be more cost-effective than the no-test option (less than euro30000 per QALY).

237 coy option influences the valuation of other options, making valuation context-dependent even when ch

238 A flexible option of both multi-use and single use intermittent cat

239 In end-stage chronic kidney disease, the option of organ transplantation is limited because of th

240 We propose that co-option of single-copy genes may be a common but relative

241 ead mounted display seems to be an effective option of treatment in adults with anisometropic amblyop

242 to evaluate the potential usefulness of this option of treatment.

243 They can even exercise the option of using the right eye or the left eye.

244 Emerging wireless options offer important capabilities that avoid some of

245 providing a tool to explore various surgical options, offering complementary information to existing

246 We assessed whether this treatment option offers any advantage over the standard protease i

247 cision between a gamble and a safe (certain) option on every trial.

248 for which there are currently no therapeutic options or available vaccines.

249 erage), ownership interests (including stock options, partnership shares), royalty or license payment

250 rrigation activities, and the role treatment options play in limiting risks.

251 RU guidelines with MR imaging when it was an option, proportions of any neoplasm and malignant neopla

252 y tuning the threshold distribution with the options' quality distribution.

253 cinoma who had exhausted all other treatment options received (177)Lu-3BP-227 for evaluation of NTR1

254 t need in this patient group and therapeutic options remain limited.

255 al imaging modality, and current therapeutic options remain uncertain but are rapidly evolving.

256 a decision tree model that compared the test option (screening of asymptomatic individuals, treatment

257 ollow-up of positive cases) with the no-test option (screening, treating, and follow-up of symptomati

258 the two best available treatment technology options specified in the 2015 Effluent Limitation Guidel

259 ymptomatic improvement, including behavioral options such as cognitive behavioral therapy, slow breat

260 to the failure of the present pharmaceutical options, such as carboplatin a metallodrug based on Pt c

261 is a significant unmet need for a treatment option that does not disrupt treatment regimens for unde

262 expanded decision algorithms and therapeutic options that are associated with improved disease nosolo

263 Moreover, the server provides additional options that can be chosen by the user depending on the

264 on microglia responses and discuss treatment options that modulate microglial phenotypes.

265 physicians choose among available treatment options, the American College of Physicians recently iss

266 des an important reference for the treatment options, therapy assessment, and rehabilitation of KOA.

267 ith the lack of available approved treatment options, there was strong motivation to investigate any

268 g MMP networks and to generate new treatment options through targeted polypharmacology.

269 ion effect, however, shows that adding a new option to a choice set can change the relative value of

270 apsule endoscopy (CE) provides a noninvasive option to assess the small intestine, but its use with r

271 Rush oral immunotherapy is a treatment option to be considered for adults with food allergy who

272 therapy is therefore believed to be the only option to further improve patient outcomes.

273 ogic miR-34a inhibition may be a therapeutic option to prevent or ameliorate HALI/BPD in neonates.

274 This information allows more options to be considered for empiric therapy, at least f

275 This has led to therapeutic options to break the cycle.

276 ehavior, and breadth of available purchasing options to identify stock-outs worldwide.

277 mendations from a two-day summit to identify options to improve drinking-water quality for N.C. resid

278 chers integrate their own data with security options to keep them private or make them publicly avail

279 orm for the development of novel therapeutic options to manage Gram-negative infections.

280 er, ClusPro also offers a number of advanced options to modify the search; these include the removal

281 ons will not only provide improved treatment options to overcome resistance, but, in the future, will

282 The development of clean label options to overcome such quality problems is currently o

283 ase (LGG), to uncovering effective treatment options to prolong patient survival in an almost univers

284 h discipline and their respective management options to provide optimal care.

285 potential value of pharmacologic therapeutic options to treat ME in patients with ERMs, we examine he

286 eriment in which one or other extreme-valued option was omitted from the learning sequence showed tha

287 in QALYs gained between the test and no test options was 4758.62 (95% CI 4618.42-4898.82).

288 years (QALYs) gained in the test and no-test option were 61 820.82 and 57 354.42.

289 tandard repair arm assigned to all treatment options were included in the standard repair group of bo

290 an change the relative value of the existing options, which is a violation of the independence princi

291 n patients unresponsive to empiric treatment options, which occurs in 10% of all cases.

292 n-valve (VIV) TAVR is a feasible therapeutic option with acceptable acute procedural results.

293 ndependently of each other and then pick the option with the highest subjective value.

294 f these paradigms will lead to new treatment options with glutaminase inhibitors and the utility of P

295 ential in discussing prognosis and treatment options with patients and to support cost-effectiveness

296 INSTI designed to improve on existing INSTI options with the backbone of emtricitabine and tenofovir

297 views the current status of available pacing options, with particular focus on His-bundle pacing.

298 e variations in all the parameters, the test option would still be more cost-effective than the no-te

299 distinct advantages over current therapeutic options, yet experimental vaccines have not been success

300 ive at reducing supply risk as the next best option, yield improvement.